title: Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.
abstract: The increase in the level of quinolone resistance of Haemophilus influenzae clinical isolates during ofloxacin therapy of a patient with recurrent respiratory infections was investigated. The first isolate (MIC of ciprofloxacin of 2 microg/ml) and the second isolate (MIC of 32 microg/ml) belonged to the same clone, as shown by pulsed-field gel electrophoresis, and the increase in the resistance level was associated with a substitution in Ser-84 to Arg in the ParC protein. These results emphasize the potential risk of development of quinolone-resistant H. influenzae during fluoroquinolone therapy in patients with recurrent respiratory infection.
authors.affiliation: Departament de Microbiologia, Institut de Investigació Biomédica August Pi i Sunyer, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain. vila@medicina.ub.es
authors.forename: J
authors.initials: J
authors.lastname: Vila
authors.forename: J
authors.initials: J
authors.lastname: Ruiz
authors.forename: F
authors.initials: F
authors.lastname: Sanchez
authors.forename: F
authors.initials: F
authors.lastname: Navarro
authors.forename: B
authors.initials: B
authors.lastname: Mirelis
authors.forename: M T
authors.initials: MT
authors.lastname: de Anta
authors.forename: G
authors.initials: G
authors.lastname: Prats
mesh_terms: D019943:Amino Acid Substitution; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology*; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D015242:Ofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000890:Anti-Infective Agents; D015242:Ofloxacin; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II